Browse drugs

…atment responses, and safety outcomes of SLE patients receiving anifrolumab in routine clinical practice. We retrospectively reviewed 7 fem…

…Background Anifrolumab is approved for adults with moderate-to-severe active systemic …

…ents with persistent disease activity despite standard therapy. Anifrolumab, a monoclonal antibody targeting the type I interferon receptor…

…nd induces NfL release in neuronal cells which is attenuated by anifrolumab. Our findings propose a role for type I IFN in neuronal injury …

…plained approximately 8% of the variance in δCLASI (R2 = 0.08). Anifrolumab was the only therapy independently associated with significant …

…h results from pivotal trials (TULIP-1 and TULIP-2), supporting anifrolumab as an effective therapeutic option for patients with SLE, altho…

…o investigate DORIS remission attainment following subcutaneous anifrolumab initiation among patients with SLE who are naïve to conventiona…

…emic Lupus Erythematosus (SLE) is a chronic autoimmune disease. Anifrolumab, a monoclonal antibody targeting the type I interferon receptor…

…al-world cohort provides clinical and mechanistic evidence that anifrolumab improves clinical outcomes, enables glucocorticoid tapering and…

…Objectives Anifrolumab is a biologic recently approved for systemic lupus erythematosu…

…arning Objectives Discuss the different mechanisms of action of belimumab and anifrolumab and their roles in modulating immune pathways i…

…al diagnosis of DADA2. Strikingly, the patient was treated with anifrolumab (an anti-interferon alpha receptor 1 antibody) that rapidly ind…